Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12671943 | 1.00 | THRB (0.41) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL12756131 | 1.00 | THRB (0.41) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL5005561 | 1.00 | THRB (0.41) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL19097103 | 1.00 | THRB (0.41) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL2632390 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL3344825 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL10877344 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL2121705 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL15573458 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT | |
| SCHEMBL1491305 | 0.98 | THRB (0.40) | THRBMEN1HTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002014548-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACIDS SAMPLE PROCESSING AND AMPLIFICATION | APPLIED GENE TECHNOLOGIES, INC. (US) | 2002-02-21 | — | — | WO | claimed |
| US-20010031473-A1 | Sample processing to release nucleic acids for direct detection | DATTAGUPTA NANIBHUSHAN (US) | 2001-10-18 | — | — | US | claimed |
| US-6242188-B1 | Sample processing to release nucleic acids for direct detection | APPLIED GENE TECHNOLOGIES, INC. | 2001-06-05 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| US-6448047-B2 | Sample processing to release nucleic acids for direct detection | APPLIED GENE TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6423497-B1 | LABELING PREFERENTIAL NUCLEOTIDE SEQUENCES; OBTAIN NUCLEIC ACIDS, INCUBATE IN AMPLIFICATION MIXTURE WITH LABEL AND BINDING AGENT, EXPOSE TO LIGHT, RECOVER PRODUCT | APPLIED GENE TECHNOLOGIES, INC. | 2002-07-23 | — | — | US | disclosed |
| US-20020061537-A1 | Stabilization of nucleic acid amplification cocktails | DATTAGUPTA NANIBHUSHAN (US) | 2002-05-23 | — | — | US | disclosed |
| US-6379930-B1 | Stabilization of nucleic acid amplification cocktails | APPLIED GENE TECHNOLOGIES, INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1192272-A2 | METHOD OF LABELING A NUCLEIC ACID AMPLICON WITH SIMULTANEOUS CONTAMINATION PREVENTION | Applied Gene Technologies, Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0281927-B1 | Assay for nucleic acid sequences in a sample | BAYER AG (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5348855-A | Assay for nucleic acid sequences in an unpurified sample | MILES INC. (US) | 1994-09-20 | — | — | US | disclosed |
| EP-0235726-B1 | RAPID DETECTION OF NUCLEIC ACID SEQUENCES IN A SAMPLE BY LABELING THE SAMPLE | MILES INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| EP-0237833-B1 | SOLUTION-PHASE HYBRIDIZATION ASSAY FOR DETECTING POLYNUCLEOTIDE SEQUENCES | MILES INC. (US) | 1993-01-13 | — | — | EP | disclosed |
| US-4968602-A | DIAGNOSIS OF GENETIC DISORDERS | MOLECULAR DIAGNOSTICS, INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0281927-A2 | Assay for nucleic acid sequences in a sample | Bayer Corporation (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0237833-A2 | Solution-phase hybridization assay for detecting polynucleotide sequences | MILES INC. (US) | 1987-09-23 | — | — | EP | disclosed |
| EP-0235726-A2 | Rapid detection of nucleic acid sequences in a sample by labeling the sample | MILES INC. (US) | 1987-09-09 | — | — | EP | disclosed |
| EP-0228075-A2 | Eucaryotic genomic dna dot-blot hybridization method | MOLECULAR DIAGNOSTICS, INC. (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | THRB 2246/4885MEN1 3152/4885HTT 1024/4885 |
| US-20220127279-A1 | MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, XIAP, TP53 | THRB 2603/4885MEN1 2852/4885HTT 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.